Published in Kidney Int on October 29, 2014
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients | NCT00866879
Regulation of innate immune cell function by mTOR. Nat Rev Immunol (2015) 1.27
BK Polyomavirus and the Transplanted Kidney: Immunopathology and Therapeutic Approaches. Transplantation (2016) 0.78
Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients. Transplant Direct (2016) 0.75
Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant Recipients. Transplant Direct (2017) 0.75
Autophagy in kidney transplants of sirolimus treated recipients. J Nephropathol (2016) 0.75
Evolving Approaches in the Identification of Allograft-reactive T and B Cells in Mice and Humans. Transplantation (2017) 0.75
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity (2008) 4.44
Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant (2004) 4.04
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet (2011) 2.82
Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med (2012) 2.62
Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol (2007) 2.61
Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood (2008) 2.53
Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int (2010) 2.38
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation (2009) 2.33
Evaluation of quality-control criteria for microarray gene expression analysis. Clin Chem (2004) 2.28
Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J Immunol (2009) 2.06
Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol (2002) 1.81
Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol (2003) 1.81
Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant (2012) 1.78
Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant (2010) 1.65
From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development. Nat Immunol (2009) 1.61
The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant (2009) 1.60
Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant (2005) 1.60
Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol (2008) 1.46
Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant (2004) 1.30
Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant (2009) 1.24
Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients. Transpl Int (2009) 1.08
Noninvasive diagnosis of acute rejection of renal allografts. Curr Opin Organ Transplant (2010) 0.98
Therapeutic targets in the treatment of allograft fibrosis. Am J Transplant (2006) 0.97
Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy. Transplantation (2011) 0.90
Hepatocellular carcinoma in HCV-infected patients awaiting liver transplantation: genes involved in tumor progression. Liver Transpl (2004) 0.87
Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation. Transplant Proc (2011) 0.86
Comparison of regulatory T cells and FoxP3-positive T-cell subsets in the peripheral blood of renal transplant recipients with sirolimus versus cyclosporine: a preliminary study. Transplant Proc (2013) 0.85
Optimal immunosuppression to prevent chronic allograft dysfunction. Kidney Int Suppl (2010) 0.83
Immune profile of pediatric renal transplant recipients following alemtuzumab induction. J Am Soc Nephrol (2011) 0.82
Effect of biologic agents on regulatory T cells. Transplant Rev (Orlando) (2011) 0.82
Circulating lymphocyte subsets in different clinical situations after renal transplantation. Immunology (2012) 0.82
Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Clin J Am Soc Nephrol (2012) 0.81
Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. Am J Transplant (2013) 0.79
Histological progression of chronic renal allograft injury comparing sirolimus and mycophenolate mofetil-based protocols. A single-center, prospective, randomized, controlled study. Pediatr Transplant (2010) 0.78